Treating thrombotic thrombocytopenic purpura without plasma exchange during the COVID-19 pandemic. A case report and a brief literature review.
Transfus Apher Sci
; 60(3): 103107, 2021 Jun.
Article
in English
| MEDLINE | ID: covidwho-1104307
ABSTRACT
We report the case of a patient diagnosed with a clinical relapse of acquired immune-mediated thrombotic thrombocytopenic purpura (TTP) who was successfully treated with low-dose rituximab plus corticosteroids without the use of plasma exchange (PEx), which was unavailable at the time due to the COVID-19 pandemic. Rituximab 100 mg weekly for 4 weeks was administered, combined with 1 mg/kg of prednisone, obtaining a complete hematological response in 6 weeks. This case suggests that PEx may be unnecessary for a subset of patients with relapsed TTP who are clinically stable without significant end-organ damage. A brief literature review regarding TTP patients treated without plasma exchange is also included.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Plasma Exchange
/
Purpura, Thrombotic Thrombocytopenic
/
COVID-19
Type of study:
Case report
/
Observational study
/
Prognostic study
/
Reviews
Limits:
Adult
/
Female
/
Humans
/
Young adult
Language:
English
Journal:
Transfus Apher Sci
Journal subject:
Hematology
Year:
2021
Document Type:
Article
Affiliation country:
J.transci.2021.103107
Similar
MEDLINE
...
LILACS
LIS